Achieve Life Sciences, Inc.
ACHVHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeAchieve Life Sciences, Inc., a late-stage pharmaceutical company, develops and commercializes cytisinicline for nicotine independence in Canada, the United States, and the United Kingdom. The company carries a $643.7M market cap, placing it firmly in the small-cap category. The company offers cytisinicline, a naturally occurring alkaloid that interacts with nicotine receptors in the brain that reduces the severity of nicotine withdrawal symptoms.
Market Cap
$643.7M
Beta
2.22
P/E (TTM)
—
P/E (Fwd)
-12.68
EPS (TTM)
$-1.07
EPS (Fwd)
$-0.49
ROE
-496.1%
ROA
-108.4%
Cash
$29.3M
Total Debt
$15.0M
Free CF
-$26.9M
52W Change
134.0%
Annual Financials
Cash vs Debt
With $29.3M in cash and $15.0M in debt, ACHV maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$26.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -496.1% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
Achieve Life Sciences, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing ACHV's risk profile alongside its fundamentals and technical indicators provides a more complete picture.